# Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia

> **NCT00838240** · PHASE1,PHASE2 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 114 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **DRUG:** idarubicin

## Key facts

- **NCT ID:** NCT00838240
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2012-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838240, "Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00838240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*